This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Microsoft Security Response Center has confirmed that a SQL Server elevation of ...

The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to ...

As conflict escalates following the US and Israeli attacks on Iran, and Iran’s subsequent retaliatory strikes, reports have emerged that Israel may have used laser weapons to shoot down rockets fired ...

Beam Therapeutics expanded its liver-targeted genetic disease technology with a new program, BEAM-304, for the treatment of phenylketonuria (PKU), a disease with significant unmet need that affects ...

Nava Public Benefit Corp. has completed the acquisition of Beam, a cloud-based product used by government agencies to administer safety net, emergency aid and cash assistance programs. Be part of the ...

As Nava acquires Beam, CEO Rohan Bhobe has lofty goals: Not only to improve what the company offers to government and the public, but to improve the entire gov tech market. The move brings together ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. The biotech is pioneering treatments based on base ...

Jim Beam will pause distillation at one of its Kentucky facilities for all of 2026 amid a market slowdown. Bourbon sales are stagnating after years of growth, while inventory has reached historical ...

(RTTNews) - Beam Global (BEEM) on Wednesday reported preliminary fourth-quarter 2025 revenue performance. Fourth quarter revenue rose more than 50 percent from the prior quarter, reflecting momentum ...

Good afternoon. Thank you for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO ...

Beam has reported progress with the FDA on a potential accelerated approval path for BEAM‑302 and plans to file a Biologics License Application (BLA) for risto‑cel as early as the end of 2026. Beam ...